On July 15, 2026, the trial registry ClinicalTrials.gov listed a status update for a study involving setmelanotide. The study, titled "Open-Label Extension Study of Setmelanotide," is registered under identifier NCT06596135. It is designated a Phase 3 trial. Its current status is recorded as completed as of this date.
The registry entry does not include results data in the information provided. No efficacy or safety outcomes are stated for this update. This brief reports only the status change and trial details as listed.
Open-label extension studies are typically designed to allow continued observation of participants who took part in earlier trial phases. The specific objectives, participant population, and duration of this extension study are not detailed in the available event data. No additional trial design information beyond phase and status was provided.
Readers seeking further detail on this study can consult the ClinicalTrials.gov listing directly for the complete registry record. For general background on setmelanotide, including its approved regulatory status, see the compound overview linked with this brief.